Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
13.10
+0.20 (1.55%)
At close: May 19, 2026, 4:00 PM EDT
13.32
+0.22 (1.68%)
After-hours: May 19, 2026, 7:38 PM EDT
Olema Pharmaceuticals Employees
Olema Pharmaceuticals had 137 employees as of March 31, 2026. The number of employees increased by 35 or 34.31% compared to the same quarter last year.
Employees
137
Change
35
Growth
34.31%
Revenue / Employee
n/a
Profits / Employee
-$1,351,467
Market Cap
1.14B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 137 | 35 | 34.31% | 137 | 0 |
| Dec 31, 2025 | 131 | 35 | 36.46% | 131 | 0 |
| Sep 30, 2025 | 122 | 34 | 38.64% | 122 | 0 |
| Jun 30, 2025 | 117 | 28 | 31.46% | 116 | 1 |
| Mar 31, 2025 | 102 | 26 | 34.21% | 101 | 1 |
| Dec 31, 2024 | 96 | 22 | 29.73% | 96 | 0 |
| Sep 30, 2024 | 88 | 18 | 25.71% | 87 | 1 |
| Jun 30, 2024 | 89 | 17 | 23.61% | 80 | 9 |
| Mar 31, 2024 | 76 | 13 | 20.63% | 75 | 1 |
| Dec 31, 2023 | 74 | -12 | -13.95% | 74 | 0 |
| Sep 30, 2023 | 70 | -5 | -6.67% | 70 | 0 |
| Jun 30, 2023 | 72 | -3 | -4.00% | 67 | 5 |
| Mar 31, 2023 | 63 | -8 | -11.27% | 62 | 1 |
| Dec 31, 2022 | 86 | 12 | 16.22% | 83 | 3 |
| Sep 30, 2022 | 75 | 14 | 22.95% | 73 | 2 |
| Jun 30, 2022 | 75 | 24 | 47.06% | 72 | 3 |
| Mar 31, 2022 | 71 | 34 | 91.89% | 70 | 1 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Maravai LifeSciences Holdings | 435 |
| Zenas BioPharma | 167 |
| DBV Technologies | 161 |
| MapLight Therapeutics | 133 |
| MoonLake Immunotherapeutics | 130 |
| Septerna | 130 |
| Savara | 70 |
OLMA News
- 6 hours ago - Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 days ago - Citi opens ‘upside 90-day catalyst watch’ on Olema Oncology - TheFly
- 6 days ago - Olema Oncology price target lowered to $35 from $38 at Guggenheim - TheFly
- 7 days ago - Olema Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 7 days ago - Olema Pharmaceuticals Earnings release: Q1 2026 - Filings
- 15 days ago - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors - GlobeNewsWire
- 20 days ago - Olema Pharmaceuticals Proxy statement: Proxy filing - Filings